$1.00
-0.40-28.57%
At close: -
$2.30
1.30130.00%
After Hours: Apr 2, 9:26 AM EDT
Comments
Loading...
Eagle Pharmaceuticals Earnings Estimates, EPS & Revenue | OTC:EGRX | Benzinga
Eagle Pharmaceuticals reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
Nov 8
EPS
–
Quarterly Revenue
–
Annual Revenue
(as of Jun 30)
(as of Jun 30)
$257.55M
Analyze the earnings history of Eagle Pharmaceuticals using advanced sorting and filters.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EGRX | Eagle Pharmaceuticals | $1.12 | $1.07 | — | — | $65.90M | $64.51M | — | — | 11/08/2023 | Get Alert |
| EGRX | Eagle Pharmaceuticals | $1.56 | $1.05 | $1.18 | 12.38% | $74.14M | $59.35M | $64.65M | 8.92% | 08/08/2023 | Get Alert |
| EGRX | Eagle Pharmaceuticals | $4.04 | $1.05 | $1.26 | 20.00% | $115.87M | $63.29M | $66.31M | 4.76% | 05/09/2023 | Get Alert |
| EGRX | Eagle Pharmaceuticals | $0.85 | $0.83 | $1.10 | 32.53% | $42.32M | $64.26M | $60.70M | -5.54% | 03/13/2023 | Get Alert |
| EGRX | Eagle Pharmaceuticals | $0.56 | $0.91 | $1.12 | 23.08% | $39.85M | $62.08M | $65.90M | 6.15% | 11/07/2022 | Get Alert |
| EGRX | Eagle Pharmaceuticals | $0.93 | $3.36 | $1.56 | -53.57% | $48.12M | $116.89M | $74.14M | -36.58% | 08/09/2022 | Get Alert |
| EGRX | Eagle Pharmaceuticals | $0.24 | $3.88 | $4.04 | 4.12% | $41.25M | $123.33M | $115.87M | -6.05% | 05/09/2022 | Get Alert |
| EGRX | Eagle Pharmaceuticals | $0.96 | $0.94 | $0.85 | -9.57% | $49.92M | $51.08M | $42.32M | -17.15% | 03/07/2022 | Get Alert |
| EGRX | Eagle Pharmaceuticals | $1.17 | $0.83 | $0.56 | -32.53% | $49.93M | $46.40M | $39.85M | -14.11% | 11/09/2021 | Get Alert |
| EGRX | Eagle Pharmaceuticals | $0.57 | $0.80 | $0.93 | 16.25% | $41.94M | $45.86M | $48.12M | 4.94% | 08/09/2021 | Get Alert |
| EGRX | Eagle Pharmaceuticals | $0.84 | $0.65 | $0.24 | -63.08% | $46.02M | $45.41M | $41.25M | -9.16% | 05/10/2021 | Get Alert |
| EGRX | Eagle Pharmaceuticals | $0.48 | -$0.17 | $0.96 | 664.71% | $48.26M | $53.16M | $49.92M | -6.10% | 03/02/2021 | Get Alert |
| EGRX | Eagle Pharmaceuticals | $0.26 | $0.28 | $1.17 | 317.86% | $41.15M | $47.02M | $49.93M | 6.18% | 11/02/2020 | Get Alert |
| EGRX | Eagle Pharmaceuticals | $0.84 | $0.26 | $0.57 | 119.23% | $56.70M | $42.28M | $41.94M | -0.81% | 08/10/2020 | Get Alert |
| EGRX | Eagle Pharmaceuticals | $1.01 | $0.57 | $0.84 | 47.37% | $49.78M | $51.10M | $46.02M | -9.94% | 05/11/2020 | Get Alert |
Eagle Pharmaceuticals (EGRX) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | 2023-08-08 | $1.18 | $1.05 | 12.4 % |
| Q1 | 2023-05-09 | $1.26 | $1.05 | 20.0 % |
| Q4 | 2023-03-13 | $1.10 | $0.83 | 32.5 % |
| Q3 | 2022-11-07 | $1.12 | $0.91 | 23.1 % |
Eagle Pharmaceuticals (EGRX) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | 2023-08-08 | $64.65M | $59.35M | 8.92 % |
| Q1 | 2023-05-09 | $66.31M | $63.29M | 4.76 % |
| Q4 | 2023-03-13 | $60.70M | $64.26M | -5.54 % |
| Q3 | 2022-11-07 | $65.90M | $62.08M | 6.15 % |
FAQ
When is Eagle Pharmaceuticals (OTCEM:EGRX) reporting earnings?
Eagle Pharmaceuticals (EGRX) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 8, 2023 for Q3.
What were the latest earnings per share (EPS) for Eagle Pharmaceuticals (OTCEM:EGRX)?
Eagle Pharmaceuticals (EGRX) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 8, 2023 for Q3 and the Actual EPS was $0.00, which missed the estimate of $1.07.
What were Eagle Pharmaceuticals’s (OTCEM:EGRX) revenues?
Eagle Pharmaceuticals (EGRX) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 8, 2023 for Q3 and the Actual Revenue was $0K, which missed the estimate of $64.5M.
Browse earnings estimates, EPS, and revenue on all stocks.